Alexion Reports Second Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alexion Pharmaceuticals (ALXN) PT Raised to $170 at Leerink Partners
July 28, 2017 10:20 AM EDTLeerink Partners raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $170.00 (from $136.00) while maintaining a Outperform rating. ALXN reported Q2 results and delivered a solid revenue and EPS beat vs. consensus. Management highlighted that the biggest contributors to the revenue growth were strong volume... More
Alexion Pharma (ALXN) Tops Q2 EPS by 30c, Sales Beat; Raises Outlook
July 27, 2017 6:31 AM EDTAlexion Pharma (NASDAQ: ALXN) reported Q2 EPS of $1.56, $0.30 better than the analyst estimate of $1.26. Revenue for the quarter came in at $912 million versus the consensus estimate of $845.53 million.
GUIDANCE:
Alexion Pharma sees FY2017 EPS of $5.40-$5.55, versus the consensus of... More
